Mary Eileen Dolan to Carmustine
This is a "connection" page, showing publications Mary Eileen Dolan has written about Carmustine.
Connection Strength
1.731
-
Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther. 2005 Dec; 315(3):1247-55.
Score: 0.268
-
Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 1993 Jul 20; 46(2):285-90.
Score: 0.116
-
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(1):59-63.
Score: 0.112
-
Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol. 1993; 32(3):221-5.
Score: 0.112
-
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992 Mar 01; 52(5):1171-5.
Score: 0.105
-
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 01; 25(4):399-404.
Score: 0.074
-
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis. 2007 May; 28(5):1111-6.
Score: 0.073
-
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther. 2004 Sep; 3(9):1127-35.
Score: 0.063
-
O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther. 2002 Sep; 1(11):943-8.
Score: 0.054
-
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83.
Score: 0.053
-
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec; 7(12):4239-44.
Score: 0.052
-
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 2000 Nov 15; 60(22):6307-10.
Score: 0.048
-
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000 Oct 15; 18(20):3522-8.
Score: 0.048
-
Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000 Oct 01; 60(19):5464-9.
Score: 0.048
-
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemother Pharmacol. 2000; 45(6):437-40.
Score: 0.045
-
O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47.
Score: 0.038
-
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1997; 39(4):307-16.
Score: 0.037
-
Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol. 1995 Oct 12; 50(8):1141-8.
Score: 0.034
-
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 1994 Sep 01; 54(17):4698-702.
Score: 0.031
-
Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994 Aug 15; 54(16):4371-5.
Score: 0.031
-
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res. 1994 Jul 01; 54(13):3487-93.
Score: 0.031
-
Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
Score: 0.030
-
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol. 1994; 35(2):121-6.
Score: 0.030
-
Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res. 1993 Sep 15; 53(18):4281-6.
Score: 0.029
-
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993; 32(6):477-81.
Score: 0.028
-
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992 Dec 16; 84(24):1926-31.
Score: 0.028
-
Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 01; 51(13):3367-72.
Score: 0.025
-
Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. Carcinogenesis. 1989 Sep; 10(9):1613-9.
Score: 0.022
-
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006 Nov; 58(5):634-9.
Score: 0.017
-
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level. J Med Chem. 1983 Nov; 26(11):1656-9.
Score: 0.015
-
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
Score: 0.012
-
Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995 Jul 01; 55(13):2853-7.
Score: 0.008
-
Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol. 1994 Nov 29; 48(11):2127-34.
Score: 0.008
-
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(6):471-6.
Score: 0.007